Healthcare provider profile · identity verified

Jimmy Ray Wesson, M.D.

Internal Medicine · SHELTON, WA · NPI 1407262496

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	645	185
Lisinopril	Lisinopril	361	93
Losartan Potassium	Losartan Potassium	297	84
Levothyroxine Sodium	Levothyroxine Sodium	292	83
Amlodipine Besylate	Amlodipine Besylate	255	77
Metoprolol Succinate	Metoprolol Succinate	223	73
Rosuvastatin Calcium	Rosuvastatin Calcium	223	68
Gabapentin	Gabapentin	221	64
Omeprazole	Omeprazole	204	64
Metformin Hcl	Metformin Hcl	190	52
Eliquis	Apixaban	148	35
Tamsulosin Hcl	Tamsulosin Hcl	148	45
Famotidine	Famotidine	120	39
Allopurinol	Allopurinol	118	30
Albuterol Sulfate Hfa	Albuterol Sulfate	113	64
Jardiance	Empagliflozin	111	33
Pravastatin Sodium	Pravastatin Sodium	106	30
Furosemide	Furosemide	102	33
Metformin Hcl Er	Metformin Hcl	102	34
Potassium Chloride	Potassium Chloride	94	37
Fluticasone Propionate	Fluticasone Propionate	92	56
Trazodone Hcl	Trazodone Hcl	84	26
Hydrochlorothiazide	Hydrochlorothiazide	83	24
Sertraline Hcl	Sertraline Hcl	83	25
Duloxetine Hcl	Duloxetine Hcl	77	22
Carvedilol	Carvedilol	75	21
Pregabalin	Pregabalin	75	25
Hydralazine Hcl	Hydralazine Hcl	65	17
Chlorthalidone	Chlorthalidone	64	19
Montelukast Sodium	Montelukast Sodium	63	22
Hydroxyzine Hcl	Hydroxyzine Hcl	61	18
Pantoprazole Sodium	Pantoprazole Sodium	61	21
Finasteride	Finasteride	55	14
Donepezil Hcl	Donepezil Hcl	54	suppressed
Ozempic	Semaglutide	52	14
Alendronate Sodium	Alendronate Sodium	51	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	48	13
Xarelto	Rivaroxaban	48	suppressed
Atenolol	Atenolol	47	13
Metoprolol Tartrate	Metoprolol Tartrate	46	17
Spironolactone	Spironolactone	46	17
Venlafaxine Hcl Er	Venlafaxine Hcl	46	13
Citalopram Hbr	Citalopram Hydrobromide	43	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	13
Clopidogrel	Clopidogrel Bisulfate	42	15
Breo Ellipta	Fluticasone/Vilanterol	41	suppressed
Ezetimibe	Ezetimibe	39	13
Alprazolam	Alprazolam	38	13
Oxycodone Hcl	Oxycodone Hcl	37	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	36	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	16
Mupirocin	Mupirocin	36	30
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	14
Glipizide	Glipizide	33	suppressed
Glipizide Er	Glipizide	33	suppressed
Lidocaine	Lidocaine	33	18
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Prednisone	Prednisone	27	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	25	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	25	11
Lovastatin	Lovastatin	24	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Ramelteon	Ramelteon	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	17
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Clonazepam	Clonazepam	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	18
Sumatriptan Succinate	Sumatriptan Succinate	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Estradiol	Estradiol	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	13
Aripiprazole	Aripiprazole	16	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Digoxin	Digoxin	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Nitroglycerin	Nitroglycerin	16	12
Primidone	Primidone	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	13
Insulin Lispro	Insulin Lispro	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Lamotrigine Er	Lamotrigine	12	suppressed
Valsartan	Valsartan	12	suppressed
Balsalazide Disodium	Balsalazide Disodium	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	11
Glimepiride	Glimepiride	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Metolazone	Metolazone	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Simvastatin	Simvastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error